ASAF stands for: Ablation of Sympathetic Atrial Fibrillation
Treatment of atrial fibrillation in patients with high sympathetic activity by pulmonary vein isolation in combination with renal denervation or pulmonary vein isolation only; an international randomized, controlled trial
The trial is designed to:
The physician-initiated, prospective, multicenter, randomized trial is currently enrolling patients in centers in The Netherlands and Spain.
The primary endpoint is time to first detection of atrial fibrillation >30 seconds, with the monitoring period starting 3 months after the intervention.
Principal investigator is Arif Elvan MD, PhD, Isala hospital Zwolle, The Netherlands.
Clinical trial information: